Dulaglutide (Trulicity®) is recommended as an option for restricted use within NHS Wales. Dulaglutide (Trulicity®) should be restricted for use in the following subpopulation / circumstances within its licensed indication for the treatment of type 2 diabetes in adults to improve glycaemic control:

• After failure, intolerance or where there is a contraindication to, standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy.
• In combination with other glucose-lowering medicinal products but not including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control, in line with current NICE guidance.

Dulaglutide (Trulicity®) is not recommended for use within NHS Wales outside of this subpopulation / these circumstances.